Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study

N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in various types of diseases. This study aimed to assess the effect of NAC on the systemic lupus erythematosus (SLE) disease activity and outcome. In this randomized, double-blind clinical trial study, 80 SLE patients were recruit...

Full description

Saved in:

Bibliographic Details
Published in:	Current controlled trials in cardiovascular medicine Vol. 24; no. 1; p. 129
Main Authors:	Abbasifard, Mitra, Khorramdelazad, Hossein, Rostamian, Abdolrahman, Rezaian, Mohsen, Askari, Pooya Saeed, Sharifi, Gholamhosein Taghipur Khajeh, Parizi, Moein Kardoust, Sharifi, Mobina Taghipour Khajeh, Najafizadeh, Seyed Reza
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 21-02-2023 BioMed Central BMC
Subjects:	Acetylcysteine Acetylcysteine - therapeutic use Anti-oxidant BILAG Blood Clinical trials Dosage and administration Double-Blind Method Double-blind studies Drug dosages Drug therapy Hematology Humans Infections Kidney Laboratories Lupus Lupus Erythematosus, Systemic - drug therapy Metabolites N-acetylcysteine Pathogenesis Pharmaceutical industry Rheumatology Severity of Illness Index SLEDAI Systemic lupus erythematosus Testing Treatment Outcome Variables Iran SLEDAI Systemic lupus erythematosus Anti-oxidant BILAG N-acetylcysteine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	N-acetylcysteine (NAC) has broadly been used as an anti-oxidant agent in various types of diseases. This study aimed to assess the effect of NAC on the systemic lupus erythematosus (SLE) disease activity and outcome. In this randomized, double-blind clinical trial study, 80 SLE patients were recruited that were classified into two groups: 40 patients received NAC (1800 mg/day; 3 times per day with 8-h intervals) for 3 months and 40 patients as the control group received normal therapies. Laboratory measurements and disease activity based on the British Isles Lupus Assessment Group (BILAG) and SLE Disease Activity Index (SLEDAI) were determined before the initiation of treatment and after the study time period. A statistically significant decrease in BILAG (P= 0.023) and SLEDAI (P= 0.034) scores after receiving NAC for a 3-month period was observed. BILAG (P= 0.021) and SLEDAI (P= 0.030) scores were significantly lower in NAC-receiving patients compared to the control group after 3 months. The disease activity in each organ based on BILAG score after treatment indicated a significant decrease in the NAC group compared to the baseline level in general (P=0.018), mucocutaneous (P=0.003), neurological (P=0.015), musculoskeletal (P=0.048), cardiorespiratory (P=0.047), renal (P=0.025), and vascular (P=0.048) complications. Analysis indicated a significant increase in CH50 level in the NAC group after treatment compared to the baseline level (P=0.049). No adverse event was reported by the study subjects. It appears that the administration of 1800 mg/day NAC to SLE patients can decrease the SLE disease activity and its complications.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1745-6215 1745-6215
DOI:	10.1186/s13063-023-07083-9